Molecular pathologic substaging in 244 stage I non-small-cell lung cancer patients: clinical implications.
David J. Kwiatkowski(Brigham and Women's Hospital), David J. Sugarbaker(Unknown), John J. Godleski(American Cancer Society), Dar-Bin Shieh, James E. Herndon(Duke University), Gary M. Strauss, William G. Richards(Brigham and Women's Hospital), Hong Xu(Xinjiang Uygur Autonomous Region Disease Prevention and Control Center), Rosa Blanco, David H. Harpole(General Marble (Greece))
Cited by 188
Related Papers
Cardiovascular Mortality and Long-Term Exposure to Particulate Air Pollution
|Circulation|2003|2.6k
Bayesian kernel machine regression for estimating the health effects of multi-pollutant mixtures
|Biostatistics|2014|1.8k
The Somatic Genomic Landscape of Chromophobe Renal Cell Carcinoma
|Cancer Cell|2014|860
Assessment of Resistance Mechanisms and Clinical Implications in Patients With<i>EGFR</i>T790M–Positive Lung Cancer and Acquired Resistance to Osimertinib
|JAMA Oncology|2018|689
A Pan-Cancer Proteogenomic Atlas of PI3K/AKT/mTOR Pathway Alterations
|Cancer Cell|2017|656